Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Moleculin Biotech Inc is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.51 |
|---|---|
| 52-week range | $1.31 - $8.78 |
| 50-day moving average | $2.01 |
| 200-day moving average | $2.92 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.70 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.51 from 2022-01-24
| 1 week (2022-01-14) | N/A |
|---|---|
| 1 month (2021-12-23) | -25.62% |
| 3 months (2021-10-22) | -45.09% |
| 6 months (2021-07-23) | -54.24% |
| 1 year (2021-01-25) | 45.19% |
|---|---|
| 2 years (2020-01-24) | 60.64% |
| 3 years (2019-01-25) | 9.42% |
| 5 years (2017-01-25) | 1.9895 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -22.94% |
| Return on equity TTM | -32.82% |
| Profit margin | 0% |
| Book value | $2.84 |
| Market capitalisation | $43.7 million |
TTM: trailing 12 months
We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.
Moleculin Biotech's shares were split on a 1:6 basis on 31 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.
Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $1.3129 up to $8.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.7243. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moleculin Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.